Glaukos (GKOS) is back in focus after the company raised its 2026 net sales guidance to a range of $680 million to $700 million, up from $620 million to $635 million previously.

Glaukos has seen strong momentum build around these updates, with a 1-month share price return of 20.58% and a year to date share price return of 52.20%, while the 1-year total shareholder return is 95.75%.

If you are looking for more stocks connected to medical technology and eye care themes, it could be a useful time to review 41 healthcare AI stocks.

Bulls point to Glaukos lifting its 2026 sales outlook and the stock’s sharp rerating. Bears highlight the ongoing net losses and rich expectations already in the price. Which side does the current valuation support?

Most Popular Narrative: 2% Overvalued

The most followed Glaukos narrative pegs fair value at $165 per share, slightly below the last close at $168.52, which frames an only modest premium.

Strong ongoing adoption and utilization of iDose TR, a first of its kind procedural pharmaceutical with a unique profile, suggests the early stages of a paradigm shift toward interventional glaucoma therapies, a substantial long term opportunity given the aging population and rising prevalence of glaucoma, likely driving robust multi year revenue and market expansion.

Curious what justifies paying up for Glaukos today. The core narrative leans heavily on fast compounding revenue, rising margins, and a rich future earnings multiple.

Result: Fair Value of $165 (OVERVALUED)

However, Glaukos still faces meaningful risks, including reimbursement pressure around iDose TR and the possibility that new glaucoma competitors cap the long term growth story.

Another View: Glaukos And The DCF Debate

The most popular narrative has Glaukos trading around 2% above an estimated fair value of $165 per share. Our DCF model points in a very different direction. It suggests fair value closer to $376.25 per share, which implies the current $168.52 price sits well below that estimate.

This kind of gap raises an important question for investors. Is the market rightly cautious about Glaukos given its losses and rich sales multiple, or is the SWS DCF model highlighting a long term opportunity that sentiment has not yet fully priced in?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Glaukos for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 57 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Glaukos clearly splits opinion right now, with strong enthusiasm on one side and clear concerns on the other. Move quickly to review the data, stress test the assumptions and weigh up the 2 key rewards and 1 important warning sign.

Looking for more ideas beyond Glaukos?

Do not stop with Glaukos. Use this momentum to refresh your watchlist with other clear, data backed ideas that could deserve a closer look.

• Target stability and income potential by scanning for companies offering reliable payouts through the 8 dividend fortresses.
• Hunt for quality at a reasonable price by checking companies that screen well on valuation using the 57 high quality undervalued stocks.
• Spot resilient businesses that aim to limit downside risk by reviewing the 89 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.